A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

被引：0
|
作者：
Ye, Ding-Wei
Gu, Weijie
Han, Weiqing
Luo, Hong
Zhou, Fangjian
He, Dalin
Ma, Lulin
Guo, Hongqian
Liang, Chaozhao
Chong, Tie
Jiang, Jun
Chen, Zhiwen
Wang, Yong
Zou, Qing
Tian, Ye
Xiao, Jun
Huang, Jian
Yang, Xinfeng
Li, Junliang
Jin, Chunlei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Ctr, Changsha, Peoples R China
[3] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[6] Peking Univ Third Hosp, Beijing, Peoples R China
[7] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[8] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China
[9] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
[10] Army Med Univ, Daping Hosp, Chongqing, Peoples R China
[11] Army Med Univ, Southwest Hosp, Chongqing, Peoples R China
[12] Tianjin Med Univ, Hosp 2, Tianjin, Peoples R China
[13] Jiangsu Canc Hosp, Nanjing, Peoples R China
[14] Capital Med Univ, Beijing Friendly Hosp, Beijing, Peoples R China
[15] USTC, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[16] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[17] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[18] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5003
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
    Kalebasty, Arash Rezazadeh
    Hammerer, Peter
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
  • [22] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
    Todenhoefer, Tilman
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Pino, Alvaro Montesa
    Ye, Dingwei
    Parnis, Francis
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 110 - 110
  • [24] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
  • [25] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
    Agarwal, Neeraj
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Plets, Melissa
    Lara, Primo
    Harzstark, Andrea
    Twardowski, Przemyslaw
    Paller, Channing Judith
    Zylla, Dylan M.
    Zibelman, Matthew R.
    Levine, Ellis Glenn
    Roth, Bruce J.
    Goldkorn, Amir
    Vaena, Daniel A.
    Kohli, Manish
    Crispino, Tony
    Vogelzang, Nicholas J.
    Thompson, Ian Murchie
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Oestreich, Makinna C.
    Brown, Sarah Jane
    Gupta, Shilpa
    Konety, Badrinath R.
    Dahm, Philipp
    Kunath, Frank
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [27] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.
    Gratzke, Christian
    Burgents, Joseph E.
    Niu, Cuizhen
    Poehlein, Christian Heinrich
    Drak, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
    Rezazadeh, Arash
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kapur, Shivani
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in the Phase 3 ARASENS Study
    Hovey, Elizabeth
    Hussain, Maha
    Tombal, Bertrand
    Saad, Fred
    Fizazi, Karim
    Sternberg, Coran
    Crawford, E. David
    Shore, Neal
    Kopyltsov, Evgeny
    Rezazadeh Kalebasty, Arash
    Bogemann, Martin
    Ye Dingwei
    Cruz, Felipe
    Suzuki, Hiroyoshi
    Verholen, Frank
    Srinivasan, Shankar
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 64 - 64
  • [30] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
12345